Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-10: Belantamab mafodotin + lenalidomide + dexamethasone vs daratumumab + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
jRCT2031240542Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoints: Progression-Free Survival (PFS) and Number of participants achieving MRD negative status. Started Mar 2025; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031240542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240542.